Clicky

Tuesday, November 3, 2026

Regulation

Delisting, cyber, auditor, and compliance

Wipro reports Q2 and half-year results for 2026

Wipro Ltd. announces its financial results for Q2 and the first half of 2026, showcasing performance in the competitive IT services sector.

Aduro Clean Technologies sets date for annual meeting

Aduro Clean Technologies Inc. announces its annual general and special meeting on November 27, 2026, focusing on financial reports and director elections.

Century Casinos faces potential delisting from Nasdaq

Century Casinos Inc. is at risk of being delisted from Nasdaq due to non-compliance with listing standards, impacting the hotels and motels industry.

Akebia Therapeutics Faces Nasdaq Delisting Due to Stock Price

Akebia Therapeutics received a delisting notice from Nasdaq due to its stock price falling below $1. The company has 180 days to regain compliance.

Strategy Inc announces key updates in finance services sector

Strategy Inc's recent filing reveals significant updates impacting the finance services sector, prompting potential shifts among competitors.

Medicus Pharma Regains Nasdaq Compliance, Avoids Delisting

Medicus Pharma Ltd. has regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting and boosting investor confidence.

Quaker Chemical Corp appoints Neil Daniels as CFO

Neil Daniels joins Quaker Chemical Corp as Vice President and Chief Accounting Officer, effective November 16, 2026, to enhance financial management.

Invesco Galaxy Solana ETF Announces New Principal Financial Officer

Invesco Galaxy Solana ETF appoints Lori Anello as Principal Financial Officer, succeeding Kelli Gallegos, who is on leave. This marks a significant leadership change.

Invesco Galaxy Bitcoin ETF appoints new financial officer

Invesco Galaxy Bitcoin ETF has appointed Lori Anello as Principal Financial and Accounting Officer, succeeding Kelli Gallegos, who is on leave.

Invesco Galaxy Ethereum ETF appoints new financial officer

Invesco Galaxy Ethereum ETF announces Lori Anello as new Principal Financial and Accounting Officer, succeeding Kelli Gallegos who is on leave.

Invesco DB US Dollar Index Bullish Fund Announces Leadership Change

Invesco DB US Dollar Index Bullish Fund appoints Lori Anello as new Principal Financial and Accounting Officer following Kelli Gallegos' leave of absence.

Invesco CurrencyShares Trust Announces Leadership Change

Invesco CurrencyShares Australian Dollar Trust announces Kelli Gallegos' leave and Lori Anello's appointment as Principal Financial and Accounting Officer.

Invesco CurrencyShares Swiss Franc Trust Names New CFO

Invesco CurrencyShares Swiss Franc Trust appoints Lori Anello as new CFO as Kelli Gallegos takes leave of absence, signaling leadership changes in the firm.

Invesco CurrencyShares Trust Appoints New Principal Financial Officer

Invesco CurrencyShares British Pound Sterling Trust appoints Lori Anello as Principal Financial Officer, succeeding Kelli Gallegos who is on leave.

American Fusion names MBP Global as new accounting firm

American Fusion, Inc. appoints MBP Global LLP as its new independent registered public accounting firm, following the resignation of JV CPA INC.

Vivos Therapeutics Confirms Compliance with Nasdaq Requirements

Vivos Therapeutics, Inc. confirms compliance with Nasdaq's stockholders' equity requirement, averting delisting risks and impacting the medical instruments industry.

Hilton to Transfer Stock Listing from NYSE to Nasdaq

Hilton Worldwide Holdings Inc. announces transfer of its stock listing from NYSE to Nasdaq, effective November 5, 2026, reflecting its growth strategy.

Moleculin Biotech announces 1-for-20 reverse stock split

Moleculin Biotech has approved a 1-for-20 reverse stock split to enhance its stock price, effective October 20, 2026.

Huntington Ingalls Industries appoints C. Michael Petters to Board

Huntington Ingalls Industries has appointed C. Michael Petters to its Board of Directors, enhancing leadership in the shipbuilding sector.

Vertex Pharmaceuticals Appoints Daniel Brennan to Board

Vertex Pharmaceuticals has appointed Daniel Brennan to its board, expanding its leadership team as it navigates the pharmaceutical industry.

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →